PharmaDepth

Company profile

MERCK & CO., INC.

NYSE:MRKBiotechnology: Pharmaceutical Preparations

Drug pipeline (226)

AssetStageRevenueTrialsStatus
KEYTRUDAapproved$7.9BQ2 2026302approved
KEYTRUDAapproved$7.9BQ2 2026302approved
GARDASILapproved$1.2BQ2 20260—
GARDASIL 9approved$1.2BQ2 20260—
M-M-R IIapproved$592.0MQ2 20260—

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (2236)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT00543465phase2terminated2004-08-012004-11-01Merck Sharp & Dohme LLC12-Week No-Rofecoxib Plus Aspirin Endoscopy Study (0782-003)
NCT00090155phase3completed2003-09-262004-11-24Merck Sharp & Dohme LLC2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED)
NCT00090246phase3completed2004-05-132005-04-06Merck Sharp & Dohme LLC2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)
NCT01028391phase3completed2007-09-012009-01-01Merck Sharp & Dohme LLC30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
NCT00761735phase3completed2007-07-012013-01-01Merck Sharp & Dohme LLC5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2)

FDA applications (152)

ApplicationApprovedTypeApplicantProducts
NDA 2208482026-07-15NDAMERCK SHARP AND DOHME LLC
NDA 2169642026-04-20NDAMERCK SHARP AND DOHME LLC
BLA 7614672025-09-19BLAMERCK SHARP & DOHME LLC
BLA 7614322025-06-09BLAMERCK SHARP & DOHME LLC
NDA 2191042024-08-30NDAMERCK SHARP AND DOHME LLC